Shell Stocks

[xZx]

METP still in accumulation mode. pps is holding well above the 50 ma, bollis are tightening now. r/m news could come at any moment as per conversations with the custodian, kip eardley. i'm thinking we'll hear by the end of 2006.

[sublime]

MAUG shell filed 10Q 11/14/06


The Company entered into a new development stage on January 1, 2006. The Company plans to seek a merger candidate.

(B) Use of Estimates

U. S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549


FORM 10-QSB


[X]

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended September 30, 2006


[ ]

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____


Commission File No. 0-25319


MAUI GENERAL STORE, INC.

(Name of Small Business Issuer in its Charter)







New York


84-1275578

(State of Other Jurisdiction of

incorporation or organization)


(I.R.S.) Employer I.D. No.)


P.O. Box 297, Hana, Maui, HI 96713

(Address of Principal Executive Offices)


Issuer's Telephone Number: [phone]



Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.


Yes [X] No [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes [ X ] No [ ]


APPLICABLE ONLY TO CORPORATE ISSUERS: Indicate the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date:

November 13, 2006

Common Voting Stock: 140,000,000

[Stock]

DJ US GAO: Secret Ownership Of US Cos Hamper Law Enforcement

11/14/2006
Dow Jones News Services
(Copyright © 2006 Dow Jones & Company, Inc.)


WASHINGTON (AP)--Federal law enforcement efforts have been hampered by the absence of information on company ownership, allowing shell companies to be used to launder money and evade taxes, government officials told Congress Tuesday.

U.S. states grant incorporation to nearly 2 million new companies a year without identifying their owners - lenience that allows people to hide their identities and shell companies increasingly to be used for illicit activities, lawmakers and congressional investigators say.

Some $15 million in international aid for improving the safety of nuclear power plants in the former Soviet Union was diverted, according to the Government Accountability Office, Congress' investigative arm. Shell companies in the United States are used to launder as much as $36 billion from former Soviet republics. Millions in taxable income are hidden in bank accounts in the Caribbean.

Shell companies exist mainly on paper and lack real operations.

The fees that new companies pay to register bring in hundreds of millions of dollars a year for the states.

"Shell corporations provide an opportunity for criminals or terrorists to engage in criminal activity while concealing the identities of the persons involved in the illegal activity," Stuart Nash, an associate deputy attorney general at the Justice Department, said in testimony at a hearing of the Senate Homeland Security and Governmental Affairs' investigative panel.

Law enforcement efforts are impeded, Nash said, "both in our domestic investigations and in our ability to assist our foreign ... counterparts in investigating their case, as a consequence of the exponential increase in the formation of such domestic shell corporations."

Officials from the Internal Revenue Service and a financial crimes division of the Treasury Department voiced similar concerns.

A report by the Government Accountability Office found that none of the 50 states customarily requires disclosure of the owners of companies that are not publicly traded. Other countries do require ownership information to be provided.

"This lack of transparency not only creates obvious vulnerabilities in our financial system, it also threatens our homeland security," said Sen. Norm Coleman, R-Minn., the panel's chairman. "Clearly, our failure to identify the owners of U.S. shell companies is a significant deficiency in our anti-money-laundering and terrorist financing efforts."

Among examples cited by the GAO report:

-Officials of U.S. Immigration and Customs Enforcement reported that a Nevada-based company received more than 3,700 suspicious wire transfers totaling $81 million over two years, but the case wasn't prosecuted because the agency could not identify the company's owners.

-The Justice Department said Russian officials used shell companies incorporated in Pennsylvania and Delaware to illegally divert $15 million in international aid intended for improving the safety of nuclear power plants in the former Soviet Union.

-The FBI found that U.S. shell companies are being used to launder as much as $36 billion coming from the former Soviet Union.

-The IRS discovered a scheme in which three individuals established U.S. shell companies to conceal nearly $9 million in taxable income in secret accounts in the Turks and Caicos Islands and other countries.


(END) Dow Jones Newswires

11-14-06 2032ET

Copyright (c) 2006 Dow Jones & Company, Inc.

[atout]

CLIK 10-QSB filed

#board-7359

http://www.sec.gov/Archives/edgar/data/925741/000114420406046272/v056679_10qsb.txt

[atout]

CAML 10-QSB filed.

#board-6840

http://www.sec.gov/Archives/edgar/data/13033/000072643506000005/camelot10q103106.txt

[jobynimble]

BDEV 10-Q filing

[atout]

SFPH-Pipex Therapeutics Merges With Sheffield Pharmaceuticals
11/06/2006 10:14
ANN ARBOR, Mich., Nov. 6, 2006 (PRIMEZONE) -- Pipex Therapeutics, Inc. (OTCBB: SFPH), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it has merged with Sheffield Pharmaceuticals, Inc.

COPREXA(tm) (oral tetrathiomolybdate)

Pipex's lead molecule, COPREXA(tm)(oral tetrathiomolybdate), is a novel, oral, anti-copper agent that has successfully completed two pivotal clinical trials for the treatment of neurologically-presenting Wilson's disease, a genetic neurodegenerative disease caused by the toxic effects of elevated levels of free copper in the central nervous system (CNS). COPREXA(tm) is a highly specific anti-copper agent unique in its ability to sequester and reduce free copper levels in the CNS.

COPREXA(tm)has also demonstrated potent anti-fibrotic effects in numerous animal models and has recently completed a 12-month, open label, phase II clinical trial for the treatment of refractory idiopathic pulmonary fibrosis (IPF). IPF is a debilitating and generally fatal disease marked by progressive scarring (fibrosis) of the lungs that affects an estimated 128,000 persons in the U.S. and is responsible for more deaths annually than breast or prostate cancer. There is currently no approved therapy for the treatment of IPF.

TRIMESTA(tm) (oral estriol)

Pipex is also developing TRIMESTA(tm) (oral estriol) for the treatment of relapse-remitting multiple sclerosis (MS). Estriol, an estrogenic molecule approved and marketed in Europe and Asia for the treatment of post-menopausal hot flashes for over 40 years but never introduced to the U.S., is a pregnancy hormone that is believed to be responsible for the high rates of spontaneous remission experienced by female MS patients during pregnancy.

TRIMESTA(tm) has completed an initial single-agent, crossover phase II clinical trial in the U.S. for the treatment of multiple sclerosis (MS) with highly encouraging results. In the relapsing-remitting MS patient group, the total volume and number of enhancing pathogenic myelin lesions (established neuroimaging measurements of disease activity in MS) decreased during the treatment period as compared to a six-month pretreatment baseline period. The median total enhancing lesion volumes decreased by 79% (p=0.02) and the number of lesions by 82% (p=0.09) within the first three months of treatment with TRIMESTA(tm). During a re-treatment phase of this clinical trial, relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion volumes of 88% (p=0.008) and a decrease in the number of lesions by 48% (p=0.04) compared with original baseline scores (8).

Anti-CD4 802-2 (cnsnqic-cyclic)

Pipex is developing a series of rationally-designed small molecule/peptidomimetic inhibitors of the highly important CD4 co-receptor of T-cells. Pipex's lead anti-CD4 molecule, Anti-CD4 802-2, is a cyclic heptapeptide that has demonstrated efficacy in a number of animal models of MS and other animal models of autoimmune disease and is currently nearing completion of a dose ranging phase II clinical trial for the prevention of graft-versus-host disease. Anti-CD4 802-2 may represent the first clinical stage, non-biologic molecule capable of inducing immune tolerance for a variety of CD4-mediated autoimmune diseases.

CORRECTA(tm) (clotrimazole enema)

Pipex is developing CORRECTA(tm), a proprietary retention enema formulation of the widely used topical antifungal agent clotrimazole, for the treatment of acute refractory pouchitis, a subset of inflammatory bowel disease related to ulcerative colitis (UC). CORRECTA(tm) is currently the subject of a double-blinded, placebo-controlled, multi-center, four-week treatment period, phase II clinical trial for acute pouchitis. This clinical trial, called the "CAPTURE" study, is currently being funded by a $750,000 grant from the FDA's Orphan Drug Group. Pipex has expanded this study to additional clinical centers in order to increase enrollment and expedite completion of the study.

EFFIRMA(tm) (oral flupirtine)

Pipex is developing EFFIRMA(tm) (oral flupirtine), a centrally-active CNS oral therapy, for the treatment of fibromyalgia syndrome (FMS) for the North American market. FMS is a common centrally-mediated pain disorder characterized by chronic diffuse pain and other symptoms. This indication is supported by successful pilot clinical data obtained by a leading neuropharmacologist to whom refractory and difficult-to-treat FMS patients are frequently referred. We have exclusively licensed an issued U.S. patent covering the use of flupirtine for the treatment of FMS. Flupirtine was originally developed by Asta Medica and has been approved in Europe since 1984 for the treatment of pain and used clinically for chronic lower back pain although it has never been introduced to the U.S. market for any indication. SOLOVAX(tm)(MS T-Cell Vaccine)

SOLOVAX(tm) represents a novel approach to potentially vaccinate MS patients against their own misguided, myelin-reactive T-cells. In our treatment, T-cells reactive to myelin antigens are collected from the peripheral blood of an MS patient, expanded, attenuated, and reintroduced to the patient as a vaccine. These reintroduced T-cells are capable of invoking immune responses which educate the regulatory immune system of the patient to recognize and eliminate myelin-reactive T-cells.

About the Merger

The merged company will be headquartered in Ann Arbor, Michigan, and will continue the business operations of Pipex. The combined company will continue to be quoted on the OTC Bulletin Board under the symbol SFPH. Pipex intends to apply for listing on either NASDAQ or the American Stock Exchange.

The Merger was structured such that a newly-formed special purpose subsidiary of Sheffield merged with Pipex in a stock-for-stock transaction in which Sheffield issued shares of Sheffield common stock to holders of Pipex shares, based on an exchange ratio that resulted in Pipex shareholders receiving 34 million newly issued common shares of Sheffield. All outstanding options and warrants to purchase Pipex common stock have been assumed by Sheffield and will be converted into options or warrants to purchase Sheffield common stock. Pursuant to a Private Stock Purchase Agreement entered into between Pipex and Michael F. Manion, a majority shareholder of Sheffield and the former Chief Executive Officer and sole director of Sheffield. Mr. Manion sold to Pipex 2,426,300 shares of common stock which shares Pipex intends to retire.

About Pipex Therapeutics, Inc.

Pipex Therapeutics, Inc. ("Pipex") is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases Pipex's strategy is to exclusively in-license proprietary, clinical-stage drug candidates and complete the further clinical testing, manufacturing and regulatory requirements sufficient to seek marketing authorizations via the filing of New Drug Applications (NDAs) with the FDA in the U.S. and Marketing Application Authorizations (MAAs) with the European Medicines Evaluation Agency (EMEA). Pipex has three majority owned subsidiaries, Effective Pharmaceuticals, Inc, CD4 Biosciences, Inc. and Solovax, Inc. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect Sheffield Pharmaceuticals, Inc. and Pipex Therapeutics, Inc. ("we" or "our") current expectations about its future results, performance, prospects and opportunities, including statements regarding the potential use of COPREXA(tm) for the treatment of neurologic Wilson's Disease and the prospects for regulatory filings for COPREXA(tm). Where possible, the Company has tried to identify these forward-looking statements by using words such as "anticipates," "believes," "intends," or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. We cannot assure you that we will be able to successfully develop or commercialize products based on our technologies, including COPREXA(tm), TRIMESTA(tm), SOLOVAX(tm), EFFIRMA(tm) or Anti-CD4 802-2, particularly in light of the significant uncertainty inherent in developing, manufacturing and conducting preclinical and clinical trials of new pharmaceuticals, and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our cash expenditures will not exceed projected levels, that we will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that we will be able to successfully obtain any further grants and awards, maintain our existing grants which are subject to performance, that we will be able to patent, register or protect our technology from challenge and products from competition or maintain or expand our license agreements with our current licensors, or that our business strategy will be successful. All forward-looking statements made in this press release are made as of the date hereof, and the Company assumes no obligation to update the forward-looking statements included in this news release whether as a result of new information, future events, or otherwise. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward- looking statements.

(1) Brewer, G.J., Askari, F., Lorincz, M.T., Carlson, M., Schilsky,
M., Kluin, K.J., Hedera, P., Moretti, P., Fink, J.K., Tankanow,
R., et al. 2006. Treatment of Wilson disease with ammonium
tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and
trientine in a double-blind study of treatment of the neurologic
presentation of Wilson disease. Arch Neurol 63:521-527.

(2) Brewer GJ et. al, Treatment of Wilson disease with ammonium
tetrathiomolybdate: III. Initial therapy in a total of 55
neurologically affected patients and follow-up with zinc therapy.
Arch Neurol. 2003 Mar; 60(3):379-85.

(3) Brewer, G.J. 2000. Wilson's Disease. Curr Treat Options Neurol
2:193-204.

(4) Brewer, G.J. 2005. Neurologically presenting Wilson's disease:
epidemiology, pathophysiology and treatment. CNS Drugs 19:185-192.

(5) Brewer, G.J., Ullenbruch, M.R., Dick, R., Olivarez, L., and Phan,
S.H. 2003. Tetrathiomolybdate therapy protects against
bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med
141:210-216.

(6) Askari, F.K., Dick, R., Mao, M., and Brewer, G.J. 2004.
Tetrathiomolybdate therapy protects against concanavalin a and
carbon tetrachloride hepatic damage in mice. Exp Biol Med
(Maywood) 229:857-863.

(7) Brewer, G.J., Dick, R., Ullenbruch, M.R., Jin, H., and Phan, S.H.
2004. Inhibition of key cytokines by tetrathiomolybdate in the
bleomycin model of pulmonary fibrosis. J Inorg Biochem
98:2160-2167.

(8) Sicotte, NL, et. al. Treatment of multiple sclerosis with the
pregnancy hormone estriol. Ann Neurol. 2002 Oct; 52(4):421-8.
CONTACT: Pipex Therapeutics, Inc.
Steve H. Kanzer, CPA, Esq., Chairman and
Chief Executive Officer
[phone]
Charles Bisgaier, Ph.D., President
[phone]

[xZx]

METP... a new one for the board. chart:

o/s 12m, float 7m

[atout]

CLIK: Up & Volume EOM

[atout]

CAML CHART

[atout]

POFG -board started today.
Looking for mods.
http://www.investorshub.com/boards/board.asp?board_id=7306

[lifegear]

ICOW 3M Float at .01----Charts-----

level II lineup to dollars....

http://66.201.236.134/export/level2.jsp?symbol=icow

[atout]

UBDT Chart

[Stock]

You still holding on to CAML? I have been watching this one for a few weeks. Odd volume. Bylaws changes. Form 3's. Just some unusual action.

I pick one a year and this is my 2007 shell.

[atout]

DSFX - new board

http://www.investorshub.com/boards/board.asp?board_id=7245

[atout]

UBDT CHART +299%

[atout]

Thanks -I have updated the I-box for UBDT

[bobkubecka]

RULE 14F-1
REPORT OF CHANGE IN MAJORITY OF DIRECTORS

INFORMATION PURSUANT TO SECTION 14(f) OF THE
SECURITIES EXCHANGE ACT OF 1934

UBRANDIT.COM, INC.
330 Clematis Street, Suite 217
West Palm Beach, FL 33401

This report is furnished by the Board of Directors of Ubrandit.com, Inc., a
Nevada corporation ("Ubrandit.com"), to the holders of its common stock, $.001
par value. Information in this report regarding Ming Liu has been provided to
Ubrandit.com by that individual.

On October 13, 2006 Michael Anthony and his personal holding company, Century
Capital Partners, LLC ("CCP"), entered into a Stock Purchase Agreement with Ming
Liu. The Stock Purchase Agreement provides that on the tenth day after this
Report is mailed to the record shareholders of Ubrandit.com, CCP will sell
50,000,000 shares of Ubrandit.com common stock to Ming Liu for a price of
$600,000. Mr. Liu will use his personal funds to pay the purchase price.

In connection with the execution of the Stock Purchase Agreement, Michael
Anthony, the sole director of Ubrandit.com, has elected Ming Liu to serve on the
Board of Directors and has submitted his own resignation from the Board. The
election and the resignation will be effective ten days after Ubrandit.com mails
this Report to its record shareholders. After that change of control, the new
Board of Directors - i.e. Ming Liu - will elect new executive officers for
Ubrandit.com. Initially, Ming Liu will be the only officer.
This report is provided for information purposes only. We are not soliciting
proxies in connection with the matters described in this report. You are not
requested to respond to this report in any way.

This report will first be mailed to the shareholders of Ubrandit.com on or about
October 16, 2006.

VOTING SECURITIES AND PRINCIPAL HOLDERS THEREOF

The only voting shares issued by Ubrandit.com are its common stock. On the date
of this Report, there are 69,092,790 shares of common stock issued and
outstanding. The following table sets forth the number of Ubrandit.com common
shares owned at this time by (a) each person who, as of the date of this Report,
owns of record, or is known by Ubrandit.com to own beneficially, more than 5% of
the outstanding Ubrandit.com common stock, (b) each current director of
Ubrandit.com, and (c) all current officers and directors as a group.

NAME AND ADDRESS AMOUNT AND NATURE PERCENTAGE
OF BENEFICIAL OWNER OF BENEFICIAL OWNERSHIP OF CLASS
Michael Anthony 50,000,000(1) 72.4%
330 Clematis Street, Suite 217
West Palm Beach, FL 33401

All officers and directors as
a group (1 person) 50,000,000 72.4%
---------------

(1) The shares beneficially owned by Mr. Anthony are owned of record by
Century Capital Partners, LLC, a limited liability company of which Mr.
Anthony is the managing member and has sole voting power.




<PAGE>

Upon the closing of the purchase and sale contemplated by the Stock Purchase
Agreement, there will still be 69,092,790 shares of common stock issued and
outstanding. The following table sets forth the number of Ubrandit.com common
shares that will be owned after the closing by (a) each person who, as of the
date of the closing, will own of record more than 5% of the outstanding
Ubrandit.com common stock, (b) each individual who will be a director of
Ubrandit.com after the closing, and (c) all individuals who will be officers
and/or directors of Ubrandit.com after the closing as a group.

NAME AND ADDRESS AMOUNT AND NATURE PERCENTAGE
OF BENEFICIAL OWNE) OF BENEFICIAL OWNERSHIP(2) OF CLASS
Ming Liu 50,000,000 72.4%
41-40 Union Street, Suite 6J
Flushing, NY 11355

All officers and directors as
a group (1 person) 50,000,000 72.4%


NEW BOARD OF DIRECTORS

Ten days after this Report is mailed to the Ubrandit.com shareholders of record,
the resignation of the current member of Ubrandit.com's Board will become
effective. On the same date, the election to the Board of Ming Liu will also
become effective. Mr. Liu will then be the only member of Ubrandit.com's Board
of Directors. Information regarding him follows:

MING LIU. Early in 2006 Mr. Liu organized Sino-American Capital Group,
LLC, which is engaged in developing business and financial
relationships between the U.S. and the People's Republic of China. From
2004 to 2005 Mr. Liu was a member of the Board and Corporate Secretary
to Advanced Battery Technologies, Inc., a Delaware holding company
whose Chinese subsidiary, ZQ Power-Tech, is engaged in the development
and manufacture of lithium-ion batteries. From 2003 to 2004 Mr. Liu was
Secretary to the Board of ZQ Power-Tech. From 1999 until 2003 Mr. Liu
was Vice President of Harbin Ridaxing Science and Technology Co., Ltd.,
a technology provider located in the City of Harbin, China. Mr. Liu is
31 years old.

NOMINATING AND AUDIT COMMITTEE

The Board of Directors will not have an audit committee or a nominating
committee immediately after the closing of the stock purchase, due to the small
size of the Board. The Board will also not have an "audit committee financial
expert."

SHAREHOLDER COMMUNICATIONS

The Board of Directors will not adopt a procedure for shareholders to send
communications to the Board of Directors until it has reviewed the merits of
several alternative procedures.




<PAGE>

RETIRING BOARD OF DIRECTORS

The following table lists certain information regarding the individual who is
currently the sole officer and director of the Company:

Term as
Director
Name Age Position Held Since
---- ---- ------------- -----
Michael Anthony 40 Chief Executive Officer, 2005
Chief Financial Officer, Director

MICHAEL ANTHONY. Mr. Anthony is the Managing Member of Century Capital Partners,
LLC. From 1999 until he formed Century Capital Partners, LLC, Mr. Anthony
consulted with various businesses, much the same way Century Capital Partners
does now, only on a less formal basis. In addition, since November 2004, Mr.
Anthony has been President and CEO of Union Equity, Inc. and its wholly owned
subsidiaries: Home Sales Express, Inc. and Preferred Properties Real Estate,
Inc.

COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

None of the directors, officers, or beneficial owners of more than 10% of
Ubrandit.com's common stock failed to file on a timely basis reports required
during the 2006 fiscal year by Section 16(a) of the Exchange Act.

EXECUTIVE COMPENSATION

Ubrandit.com did not pay any compensation to any of its officers or directors
during the past three fiscal years, nor did it issue stock options or other
equity grants to any of its officers or directors in that period.

October 16, 2006 By Order of the Board of Directors:

Michael Anthony, Chairman



</TEXT>
</DOCUMENT>

[atout]

FYI: UBDT board restarted
http://www.investorshub.com/boards/board.asp?board_id=5259

[atout]

LFZA - U.S. Sustainable Energy Corp.

http://biz.yahoo.com/iw/061011/0171227.html

U.S. Sustainable Energy Corp., A Mississippi Corporation, Announces Reverse Merger With Laforza Automobiles Inc.
Wednesday October 11, 8:30 am ET


NATCHEZ, MS--(MARKET WIRE)--Oct 11, 2006 -- U.S. Sustainable Energy Corp., A Mississippi Corporation ("US Sustainable," "USSEC" or "the Company") announced today that it has executed and completed a binding definitive agreement providing for USSEC's reverse acquisition of Laforza Automobiles Inc. "LFZA" (Other OTC:LFZA.PK - News). Pending shareholder approvals and customary processes, the company expects to change its name to U.S. Sustainable Energy Corp and immediately request a new ticker symbol reflective of the new business.


John Rivera, CEO of U.S. Sustainable Energy Corp "USSEC," stated, "We are extremely pleased to announce our entry into the public marketplace. After searching for the best vehicle to go public, we ultimately decided to complete this transaction with LFZA. USSEC holds patent pending technology for a new breakthrough biofuel and carbon based fertilizer. USSEC has successfully demonstrated the most cost effective method of producing biofuel estimated at $.50/ gallon according to exhaustive studies and independent Lab confirmation. The company has developed the process, units and catalyst that will transform agricultural biomass into biofuel and fertilizer. This technology offers a solution for foreign oil dependence, balancing industrial and agricultural concerns with environmental issues and stabilizing and eventually reversing global greenhouse gas emissions. Our research and development has successfully demonstrated the core technology in our fully functional facility located in Port Gibson, MS. The company is currently pursuing fully scalable implementation and deployment at further locations."

Commenting further, Mr. Rivera stated, "Unlike other biomass gasification, the USSEC process can operate at a variety of scale, converting even waste biomass into fuel and fertilizer. The fuel produced will ultimately be more valuable than ethanol or methanol, and the USSEC process can convert biomass materials at an efficiency that cannot be matched by currently planned operations. In addition, unlike virtually all other approaches for biomass to energy, which deplete soil nutrients, the USSEC process restores and enhances soil mineral and carbon content. As a direct result of this revolutionary approach to integrated energy and fertilizer production from biomass, the USSEC process effectively removes Greenhouse Gases from the atmosphere, and can do so profitably before the value of Green Certificates and Carbon Credits are considered."

Andrew S. Austin, interim director of LFZA specializing in corporate turnarounds and management acquisitions, commented that "USSEC's business model and intellectual properties are outstanding opportunities to return value to Laforza's shareholders." Mr. Austin also cited USSEC's intellectual properties and strategic plans as "comprehensive, organized and structurally sound," adding that "the USSEC proprietary processes have revolutionary implications on not just lessening the United States' dependency on fossil fuel, but also providing an efficient energy model for multiple applications facilitating broad positive economic benefits to other sectors of the United States economy like farming."

For further information on the company, please visit www.ussec.us

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press release and some oral statements are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and the Company has no specific intention to update these statements.



Contact:
For further information please contact:
Redwood Consultants, LLC
415-884-0348
Email Contact



--------------------------------------------------------------------------------
Source: U.S. Sustainable Energy Corp.

[opas60]

BSOI - what's up with this one ?

Very clean shell , no debts , pending law suits etc., extremely low float ( on 04/30/2006 just 888,180 outstanding ) , in past 5 years former CEO Mr. Martin flatly refused several RM candidates
( " you should have at least 100M$ bussines" ) and still -
NOTHING happened !

Do everybody have any fresh info on this one - if this is the case let us know ...

[lifegear]

LBPE is fluctuating a bit .002x.03 but it was an uptick today

[lifegear]

should DTEK breakout of .009-.01 resistance, could go ballistic.....per Company, they're looking to reverse merge--not sure how much of the 8.5M o/s belongs to insiders

[Mr. Bill]

Yes, another good low priced shell with an even greater insider %

[lifegear]

JPEI 14M O/S--insiders own 95% of O/S

[Mr. Bill]

CIBM .005 x .008 Cheapest pink shell out there. CEO owns about 50% of common OS

[originunknown]

OGAM - 0.03. +7%
High of day .04
HSDN doing a lot of the buying

[opas60]

OGAM - 0.028 , +50% .
Do anybody have any info what's going on whit this one ?
I believe that this is one of the Keating shells ...

[lifegear]

here's the one for DTEK....

http://ww3.ics.adp.com/streetlink_data/dirDTEK/sa639E.pdf

[lifegear]

did you see the one for DTEK lately?

[wildbill]

very interesting bally i personally cant wait to see what develops might take some time but...fingers crossed glty

[ballyhooo]

Yes, but the reference was towards Carerra Capital and Mr. Becker! This is not the first deal for them!!! eom

[lifegear]

are you talking about POFG former USPS symbol?

[ballyhooo]

Found this on SI!!!

Hello fellow USPS shareholders. Happy New Year to everyone.

I am posting to see if anyone else received a proxy regarding USPS. A merger and acquisition firm, Carrera Capital, Inc. held a shareholder meeting Friday, December 30, 2005. I did not receive the proxy until Saturday, December 31, 2005.

Do any of you know the president of USPS (?? Dave Gardner ??) or know how to contact him to see what he has to say about this?

What are your opinions on this. Is there any chance the current management will ever resurrect the company. Is this action good news, bad news, or does it not make any difference. Our shares are not worth much now as it stands, but I don't feel too good about being acquired by another company and end up with just one share for every 10,000 shares I currently own.

Is there anyone reading this message board that has experience with this and can tell us what is happening and what to expect?

Should we band together and fight this action or should we be glad and go along with it?

Can we do anything about the shareholder meeting being held before we received the proxy material, like force them hold another meeting after everyone has had time to respond to the proxy. Who would we contact?

Thanks in advance.
Ron


A letter included with the proxy says
- USPS is not operating and has been abandoned by if former officers.
- USPS has been administratively dissolved by the state of Nevada for failure to pay annual fees.
- USPS terminated its relationship with its transfer agent, abandoning shareholder records.
- The company (USPS) has not responded to inquires for current information regarding its quotation on the Pink sheets quotation system.
- The company has not held a shareholder meeting in over 13 months.
- The company has failed to file state or federal tax returns.


The sole purpose of the proxy and shareholder meeting is to select a new director. The one they are nominating is

Chris Allen
who is CEO of
Carrera Capital, Inc.
Mergers & Acquisitions
2425 E. Camelback Rd, Suite 1075
Phoenix, AZ 85016
Telephone [phone]

The letter also says that Carrera Capital, inc. has several viable businesses which may be interested in merging with USPS, but in order to do so, each shareholder should vote in the shareholder meeting (to elect Chris Allen I presume).

The letter also says Mr. Allen's primary area of focus include:
- Addressing the entity's outstanding financial obligations, including, but not limited to, state and federal tax debts, monies owed to vendors and corporate filing fees and franchise taxes owed to states.
- Locating and updating state filings, board of minutes, articles of incorporation, and other corporate books and records.
- Finding merger and acquisition candidates for the purpose of resurrecting business operations in the previously default entity.
- Opening and maintaining communication with shareholders by conducting shareholder meetings and issuing notices.

It then lists David B. Stocker as corporate counsel. He specializes in representing small and mid-size private and public companies, their officers and directors. He can be reached via email at [e-mail] or the telephone number referenced above.

http://www.siliconinvestor.com/readmsg.aspx?msgid=22018280

[wildbill]

CAVR .007 20 mil os 8k -

found http://stockerlaw.com/ couldnt find carrera capital inc though



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549



FORM 8-K



CURRENT REPORT



Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of earliest event reported) August 8, 2006





CARVER CORPORATION

(Exact name of registrant as specified in its chapter)











WASHINGTON


000-14482


91-1043157

(State or other jurisdiction of incorporation)


(Commission File Number)


(IRS Employer Identification No.)









2425 East Camelback Road, Suite 1075, Phoenix, Arizona 85016

(Address of principal executive offices) (Zip Code)





Registrant’s telephone number, including area code: 602-852-5445





(Former name or former address, if changed since last report)





Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





- 1 -







SECTION 1 - REGISTRANT’S BUSINESS AND OPERATIONS



Item 1.01 - Entry into a Material Definitive Agreement



The undersigned believes that the registrant has not engaged in any material business operations for the last few years. The registrant has not filed the periodic reports required by the Securities and Exchange Commission since August, 1998. In addition, on or about July 31, 2005, the registrant’s corporate charter went into default with the Washington Secretary of State. Accordingly, it is believed that the registrant had abandoned its business.



Pursuant to its ORDER APPOINTING DAVID B. STOCKER AS CUSTODIAN OF CARVER CORPORATION dated August 8, 2006 (the “Order”), the Superior Court of Washington for Spokane County appointed David B. Stocker as custodian of the registrant, and authorized Mr. Stocker to take the following actions on behalf of the registrant:






•


Appoint new officers and board of directors for the registrant within 30 days of the Notice of Entry of the Order;






•


Reinstate the registrant’s articles of incorporation;






•


Locate the financial records of the registrant to file tax returns and information statements to permit it to resume its status of good standing;






•


Obtain copies of the registrant’s shareholders lists; and,






•


Any and all further actions on behalf of the registrant as permitted by the Court and the corporate laws of the State of Washington to otherwise restore the business and prospects of the registrant for the benefit of all shareholders of the registrant.



In accordance with the Order, Mr. Stocker appointed himself as sole interim director and president. In addition, the registrant hired Carrera Capital, Inc., a business consulting firm (“CCI”), for the purpose of assisting the registrant in its efforts to salvage value for the benefit of its shareholders. CCI has also agreed to advise the registrant as to potential business combinations. Mr. Stocker, an attorney, is the president of CCI.



As of September 6, 2006, CCI has contributed approximately $15,000 and obligated itself to contribute an additional $5,000 as paid in capital to the registrant. The registrant is to use these funds to pay the costs and expenses necessary to revive the registrant’s business operations. Such expenses include, without limitation, fees to reinstate the registrant’s corporate charter with the State of Washington, payment of all past due franchise taxes, settling all past due accounts with the registrant’s transfer agent, and accounting and legal fees. CCI has agreed to continue to contribute such additional funds as are necessary to accomplish these goals.





- 2 -







In consideration for these services and capital contribution(s), the registrant issued 10,300,000 shares of its common stock to CCI representing approximately 51.5% of its common stock outstanding as of September 6, 2006.



SECTION 3 - SECURITIES AND TRADING MARKETS



Item 3.02 - Unregistered Sale of Equity Securities



On September 6, 2006, the registrant issued to 10,300,000 shares of its common stock to CCI in exchange for $20,000. See Item 1.01 above.



SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT



Item 5.01 - Changes in Control of Registrant



Pursuant to the Order and the arrangement with CCI, the registrant issued 10,300,000 shares of its common stock to CCI representing approximately 51.5% of the common stock outstanding as of September 6 2006. See Item 1.01, above.



Item 5.02 - Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers



Pursuant to the Order, David B. Stocker has been appointed sole director and officer of the registrant. See 1.01, above.



SECTION 8 - OTHER EVENTS



Item 8.01 - Other Events



At the direction of David B. Stocker, and as of this date, the registrant intends to update all regulatory filings and establish business operations that will enhance shareholder value.











- 3 -







SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: September 6, 2006

CARVER CORPORATION



By: /s/ David B. Stocker

Name: David B. Stocker

Title: Interim Director

[opas60]

CAML - low OS, tinny float - some action in last days ...

[PDC ™]

added .031 exgp

[PDC ™]

exgp shell. something might be up.

[Stock Lobster]

I bought a tiny position, out of curiosity. Then I've been trying to find out more about these stocks that are waking up out of the blue, and flying thousands of percent points.

I had a call into SMKG (formerly enlighten software) to find out more, but no luck yet.

[lifegear]

did you get some of it at lower pps?

[lifegear]

grab some at .085 =)

[PDC ™]

yep .09x2 1.00 then 10

[lifegear]

UBSS at $10.00 ask still?

[PDC ™]

GNCE :)

Posted by: PDC ™
In reply to: None Date:5/25/2006 2:25:13 PM
Post #of 9690

5,205,458 os per TA GNCE ...

[Stock Lobster]

SFTW still up 1900% from open, was up 400% on 124,000 volume. Float must be miniscule. Don't know what the story is, or why it woke up Friday.

[pelicaninnc]

Awesome! Totally forgot i had that in the mix. Tight low floats when they move they go like gangbusters.

[lifegear]

wow...OCRI up 180% today====Chart====

[lifegear]

CPSL only 44K o/s $1.25

[sublime]

wowza bill...hope u held thru the deal....heckuva chart..lol

[RagingFans]

GOMD - put her back on your radar. Been quite abit of activity